Beyond Barriers

A novel technology platform
for the delivery of therapeutics
across biological barriers

Gate2Brain

The solution

Gate2Brain
Technology

Gate2Brain (GB2) uses a novel technology platform for the delivery of therapeutics. Our platform is based on three families of peptide shuttles that improve the biopharmaceutical properties of cargoes such as small molecules, peptides, nanoparticles, proteins and antibodies in vitro and in vivo when conjugated to them.

The G2B technology platform is applicable to therapeutic areas in which biological barriers hinder the delivery and activity of drugs.

Read more

About us

Gate2Brain is a biotech company focused on the development of therapeutics that efficiently cross biological barriers such as the blood-brain barrier. We pursue our goals using a radically innovative peptide-based patented technology platform.

Technology

Gate2Brain (G2B) has a proprietary novel technology platform for the delivery of therapeutics across biological barriers.

Medicines beyond barriers

We go beyond physiological and disease barriers, as our portfolio of peptide shuttles cover barriers such as the blood-brain,
blood-retinal, skin and tumor barriers.
We go beyond economic barriers, such as the lack of investment for the development of pediatric drugs. We go beyond societal barriers to provide medicines for everyone, everywhere.

Clinical Focus

Therapeutic
Proof of Concept

Our G2B therapeutic-peptide shuttle conjugates carry the drug cargo candidates to the target site in which the disease arises. G2B-002, our flagship product and proof-of-concept of the technology, offers a new therapeutic approach with improved biopharmaceutical properties and potent activity against rare pediatric cancers.

Our objective is for G2B-002 to reach Phase 1 clinical trials and thus have a high social impact focused on the unmet medical needs of:

Rare illnesses
Pediatric patients
Oncologic diseases

G2B-002 shows potent preclinical activity for rare pediatric cancer indications such as pediatric high-grade gliomas, DIPG, Ewing sarcoma, rhabdomyosarcoma and neuroblastoma.

  • Gate2Brain
  • Gate2Brain
  • Gate2Brain

News & Media

Welcome to our news section, which provides a selection of our coverage in the media, industry, latest developments, plus videos, and more.

The Barcelona Deep Tech Award is part of the Barcelona Deep Tech Node initiative, which aims to support deep tech startups and spin-offs by facilitating their access to the market and international projection 🌐 and fostering the Deep Tech ecosystem in Barcelona.Barcelona Activa

Gate2Brain finalist in the Barcelona Deep Tech Award

,
Gate2Brain has been selected finalist in the Barcelona Deep Tech Awards together with the four startups:…
internship Eada

EADA Master students at Gate2Brain

As part of their International Master in Management and International Master in Pharmaceutical and Biotechnology…
Nadia Calviño, First Vice President of the Government and Minister of Economic Affairs visits Gate2BrainSJD

Nadia Calviño, First Vice President of the Government visits Gate2Brain

Nadia Calviño, First Vice President of the Government and Minister of Economic Affairs, and Maria Eugènia…
It’s Gate2Brain second anniversary!! 🎂 The creativity, work and dedication of Gate2Brain's team can only be matched with its desire to bring medicines beyond barriers.Gate2Brain

Gate2Brain second anniversary

It’s Gate2Brain second anniversary!! The creativity, work and dedication of Gate2Brain's team can…
Gate2Brain participated on June 29 at The Milner Therapeutics Institute (MTI) Pitch Day 🗣️at the University of Cambridge, the cradle of cancer research. The MTI Pitch Day is a great initiative designed to highlight companies like us to investors, to create connections between academic entrepreneurship and investment to promote therapeutic companies. A great event that pulls together on one side academic, preclinical and research and on the other industry in an effort to push forward collaborative drug development and increase the standard of patient care

Gate2Brain at MIT Pitch Day at University of Cambridge

Gate2Brain participated on June 29 at The Milner Therapeutics Institute (MTI) Pitch Day at the University…
Una tecnología para ayudar a tratar el cáncer infantilgate2brain

A technology to help treat pediatric cancer

Una tecnología para ayudar a tratar el cáncer infantil Expansión. Madrid . La tecnología de…

Many drugs do not reach the brain and Gate2Brain technology helps to overcome that bottleneck

Meritxell Teixidó: “Una gran quantitat de fàrmacs no arriben al cervell, i la tecnologia de Gate2Brain…

‘Tractor’ proteins that carry drugs to the brain as therapy for incurable pediatric cancer

Estas proteínas 'tractor' remolcan los fármacos hasta el cerebro como terapia contra un cáncer infantil…
Els valors de la Universitat La UB reivindica la seva identitatUniversitat de Barcelona

Gate2Brain’s CEO part of the values campaign of the University of Barcelona under the motto “I am Innovative”

Els valors de la Universitat La UB reivindica la seva identitat El transport públic, els mitjans de…

1
2
Gate2Brain
1

Making therapies a reality for patients by addressing unmet medical needs.

2

Improving patients’ quality of life using a technology that provides superior drug transport efficacy.

Go Beyond Barriers & Contact Us

Barcelona Scientific Park
Baldiri Reixac, 4-8, Torre I
08028 Barcelona, Spain
info@gate2brain.com

Gate2Brain
Gate2Brain
Gate2Brain
Gate2Brain
Gate2Brain